Definitive Contract 75N93018C00017
Award Date
7/26/18
Potential Completion Date
4/30/21
Potential Value
$600K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Antagen Biosciences Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Boston, MA 02118, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, has been awarded a $299,998 firm fixed price Small Business Innovation Research (SBIR) contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. Under this contract, Antagen will further develop its novel protein nanoparticle-based expression and delivery system using FcRider technology and antibody afucosylation technology to produce an engineered HIV envelope glycoprotein...
This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
This $1,000,000 firm-fixed-price SBIR Phase II contract was awarded by the Centers for Disease Control and Prevention (CDC) to Antagen Biosciences Inc., a minority-owned, small disadvantaged business. The contract is for research and development of an engineered HIV envelope glycoprotein and novel vaccine adjuvants to enhance the efficacy of vaccines against infectious and immune-mediated diseases. This award is part of Antagen's broader portfolio of SBIR contracts, including prior awards from...
<p>This is a $25,119,949.00 cost plus fixed fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to MacroGenics, Inc. for the development of "Dual Affinity Re-targeting Molecules for HIV-1 Suppression". The contract has an ultimate completion date of October 31, 2024 and is part of NIAID's Division of AIDS (DAIDS) program. No set-aside designation was used for this award.</p>
This is a $599,999 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Parabon NanoLabs, Inc., a small business. The objective of the contract is to develop a DNA-based HIV vaccine that will stimulate production of broadly neutralizing antibodies against the HIV-1 envelope protein trimer antigen. This is a Phase I Small Business Innovation Research (SBIR) contract under the...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services (HHS), to Aalto Bio Reagents Limited, a for-profit limited liability company. The award, valued at $9,204.00, is for the purchase of 13 vials of 2 mg each of "AFFINITY PURIFIED SHEEP ANTI-HIV-1-GP120" at $728.00 per vial. The contract has a firm fixed price and an ultimate completion date of March 31, 2014. The...
This federal contract award, valued at $499,879.67, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Southern Research Institute, a non-profit research organization. The contract is for the identification of lead compounds to inhibit HIV, as part of NIAID's broader "In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides" program. The contract is a Delivery Order...
<p>This is a $187,493.00 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Mogene Clinical Diagnostics, LC, a small disadvantaged business. The contract is for the development of a "METHOD FOR THE DETECTION OF MINORITY POPULATIONS OF DRUG RESISTANT HIV". The award was made on August 11, 2016 with a final completion date of June 14, 2017.</p>
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The $99,299 cost-plus-fixed-fee delivery order was placed under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase I clinical trials for therapeutic products targeting infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General Dynamics...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services. The contract, valued at $3,731,476.00, is for the NIAID Preclinical Development Support program, specifically to support the production and testing of ADC6-HIV GP140 and ADC7-HIV GP140. The prime contractor is Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods that specializes in the...